Lipertance

Amlodipine besilate, Perindopril arginine and Atorvastatin calcium trihydrate, the active ingredients in Lipertance, are a combination of a calcium channel blocker, an ACE inhibitor and an HMG‑CoA reductase inhibitor presented as a tablet for oral use. It treats hypertension and hyperlipidemia in adults at risk of cardiovascular events.

GNH USA supplies Lipertance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipertance acts on cardiovascular pathways to control blood pressure and lipid levels. - Hypertension: lowers systolic and diastolic pressure through vasodilation and renin‑angiotensin blockade. - Hyperlipidemia: reduces LDL‑cholesterol and triglycerides by inhibiting cholesterol synthesis. - Prevention of cardiovascular events: decreases the risk of myocardial infarction, stroke and related complications in high‑risk patients.

Lipertance may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness or light‑headedness: related to blood‑pressure lowering. - Peripheral edema: swelling of ankles or lower legs. - Cough: dry throat irritation from ACE inhibition. - Muscle pain or weakness: associated with statin component. - Gastrointestinal upset: nausea, abdominal discomfort or dyspepsia.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or airway. - Severe liver injury: jaundice, elevated transaminases, hepatic failure. - Rhabdomyolysis: muscle breakdown with dark urine and renal risk. - Marked hypotension: symptomatic low blood pressure. - Myocardial infarction: rare paradoxical cardiac events. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating Lipertance, several safety considerations should be reviewed. - Blood pressure monitoring: check regularly during initiation and dose adjustments. - Liver function assessment: evaluate baseline enzymes and monitor periodically due to the statin component. - Renal function evaluation: assess kidney status, especially in patients on perindopril. - Pregnancy and lactation: avoid unless clearly indicated and benefits outweigh risks. - Drug interaction review: identify concomitant medicines that may alter efficacy or safety. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lipertance can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Potassium‑sparing diuretics: increase risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise atorvastatin exposure and muscle toxicity. - ACE inhibitor combined with ARB or direct renin inhibitor: additive renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Other CYP3A4‑metabolised statins: monitor for myopathy. - Beta‑blockers: enhanced blood‑pressure lowering may require dose adjustment.